Cargando…
A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
Several tyrosine kinase inhibitors (TKIs) have been developed as targeted therapies to inhibit the oncogenic activity of several tyrosine kinases in chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), gastrointestinal stromal tumor (GIST), and other diseases. TKIs have significantly impro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772831/ https://www.ncbi.nlm.nih.gov/pubmed/36568202 http://dx.doi.org/10.3389/fonc.2022.1036437 |
_version_ | 1784855066136543232 |
---|---|
author | Qian, Honglan Gang, Dongxu He, Xiaoyu Jiang, Songfu |
author_facet | Qian, Honglan Gang, Dongxu He, Xiaoyu Jiang, Songfu |
author_sort | Qian, Honglan |
collection | PubMed |
description | Several tyrosine kinase inhibitors (TKIs) have been developed as targeted therapies to inhibit the oncogenic activity of several tyrosine kinases in chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), gastrointestinal stromal tumor (GIST), and other diseases. TKIs have significantly improved the overall survival of these patients and changed the treatment strategy in the clinic. However, approximately 50% of patients develop resistance or intolerance to imatinib. For second-generation TKIs, approximately 30%–40% of patients need to change therapy by 5 years when they are used as first-line treatment. Clinical study analysis showed that the T315I mutation is highly associated with TKI resistance. Developing new drugs that target the T315I mutation will address the dilemma of treatment failure. Olverembatinib, as a third-generation TKI designed for the T315I mutation, is being researched in China. Preliminary clinical data show the safety and efficacy in treating CML patients harboring the T315I mutation or who are resistant to first- or second-line TKI treatment. Herein, we review the characteristics and clinical trials of olverembatinib. We also discuss its role in the management of CML patients. |
format | Online Article Text |
id | pubmed-9772831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97728312022-12-23 A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia Qian, Honglan Gang, Dongxu He, Xiaoyu Jiang, Songfu Front Oncol Oncology Several tyrosine kinase inhibitors (TKIs) have been developed as targeted therapies to inhibit the oncogenic activity of several tyrosine kinases in chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), gastrointestinal stromal tumor (GIST), and other diseases. TKIs have significantly improved the overall survival of these patients and changed the treatment strategy in the clinic. However, approximately 50% of patients develop resistance or intolerance to imatinib. For second-generation TKIs, approximately 30%–40% of patients need to change therapy by 5 years when they are used as first-line treatment. Clinical study analysis showed that the T315I mutation is highly associated with TKI resistance. Developing new drugs that target the T315I mutation will address the dilemma of treatment failure. Olverembatinib, as a third-generation TKI designed for the T315I mutation, is being researched in China. Preliminary clinical data show the safety and efficacy in treating CML patients harboring the T315I mutation or who are resistant to first- or second-line TKI treatment. Herein, we review the characteristics and clinical trials of olverembatinib. We also discuss its role in the management of CML patients. Frontiers Media S.A. 2022-12-08 /pmc/articles/PMC9772831/ /pubmed/36568202 http://dx.doi.org/10.3389/fonc.2022.1036437 Text en Copyright © 2022 Qian, Gang, He and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qian, Honglan Gang, Dongxu He, Xiaoyu Jiang, Songfu A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia |
title | A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia |
title_full | A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia |
title_fullStr | A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia |
title_full_unstemmed | A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia |
title_short | A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia |
title_sort | review of the therapeutic role of the new third-generation tki olverembatinib in chronic myeloid leukemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772831/ https://www.ncbi.nlm.nih.gov/pubmed/36568202 http://dx.doi.org/10.3389/fonc.2022.1036437 |
work_keys_str_mv | AT qianhonglan areviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT gangdongxu areviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT hexiaoyu areviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT jiangsongfu areviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT qianhonglan reviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT gangdongxu reviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT hexiaoyu reviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia AT jiangsongfu reviewofthetherapeuticroleofthenewthirdgenerationtkiolverembatinibinchronicmyeloidleukemia |